Beyond the Scale: Do GLP-1RAs Offer More Than Weight Loss in PsA? Save

Over 70% of patients with psoriatic arthritis (PsA) struggle with excess weight, amplifying synovio-entheseal inflammation and blunting biologic response. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of injectable medications that mimic a gut hormone to reduce appetite, promote weight loss, and, increasingly, appear to dampen inflammation beyond their metabolic effects. The rapid uptake of GLP-1RAs in rheumatology has raised an urgent mechanistic question: are clinical gains in PsA driven purely by weight reduction, or do these agents carry intrinsic anti-inflammatory properties?

EULAR 2026 offered six abstracts that together illuminate, without fully resolving, this question.

RISE registry: PsA leads GLP-1RA uptake across rheumatic diseases

McCormick et al. (OP0112) analysed 60,206 RMD patients on semaglutide or tirzepatide in the ACR's RISE registry through Q3 2024. Uptake surged in 2023, and PsA patients showed the highest weight-loss treatment use of any RMD diagnosis at 6.4% — ahead of ankylosing spondylitis (5.0%) and rheumatoid arthritis (3.7%). Among 40,006 new users, tirzepatide outperformed semaglutide: non-diabetic TIR users lost 8.0% of body weight at 12 months versus 6.0% with SEM, with non-diabetic users losing more than diabetic users across both agents. Disease activity data are forthcoming, but the registry confirms GLP-1RAs have crossed firmly into rheumatology practice, with PsA patients leading the way.

TOGETHER-PsA: early joint gains before the weight drops

Coates et al. (OP069) randomised 271 overweight/obese PsA patients 1:1 to ixekizumab plus tirzepatide (IXE+TZP) or ixekizumab alone. The co-primary endpoint, ACR50 plus ≥10% weight loss at week 36, was achieved by 31.7% of the combination arm versus 0.8% with IXE alone (p<0.001). More telling was the early ACR50 divergence at week 4 (11.1% vs 3.9%, p=0.029), before meaningful weight loss could account for the difference. DAPSA LDA and MDA rates favoured the combination from week 12 onward. At week 36, 33.5% vs 20.4% achieved an ACR50 response. The trial bundles metabolic and possible direct anti-inflammatory effects of tirzepatide, but the early joint separation is difficult to explain by adiposity reduction alone.

“Weight loss per se is a powerful driver of disease improvement, but the early ACR50 divergence at week 4 and the BMI-adjusted pain signal suggest something more is at work.”

DIPSA: weight loss matters, regardless of how you achieve it

The DIPSA trial (Eder et al., OP070) provides a vital counterpoint. Among 92 patients randomised to a Mediterranean diet, low-calorie DASH, or standard dietary advice, all groups showed similar improvements in DAPSA at week 24, with no between-group differences. Crucially, the magnitude of weight lost — independent of dietary strategy — correlated significantly with improvements in DAPSA, pain, fatigue, and tender joint count. The message is clear: weight loss itself is a meaningful therapeutic lever in obese PsA patients, complicating any attempt to attribute GLP-1RA benefits to drug-specific mechanisms.

Real-world evidence: a weight-independent signal emerges

Mehta et al. (OP074) addressed the independence question most rigorously in a nested case-control study within a longitudinal PsA cohort (n=74 matched pairs). GLP-1RA use was associated with per-month reductions in cDAPSA (β −0.41; 95% CI −0.78 to −0.03) and patient pain (β −0.12; p<0.05). After adjusting for BMI change, these associations persisted — suggesting effects beyond weight loss. No significant impact was seen on swollen/tender joint counts, CRP, or PASI, indicating a nuanced signal concentrated in composite scores and patient-reported outcomes.

The TriNetX global network

At scale, Almodóvar et al. (POS0194) matched 1,534 PsA/axSpA patients on GLP-1RAs against controls in the TriNetX global network. Concomitant GLP-1RA use was associated with greater 3-year b/tsDMARD persistence (90.2% vs 86.5%; p=0.01), lower all-cause mortality (HR 0.65; p<0.001), reduced hospitalisation (HR 0.82; p<0.001), and lower stroke risk (HR 0.60; p<0.001). 

Propensity-matched series

Venerito et al. (POS0050), in a smaller propensity-matched series, found superior PsAID-12 PASS (48% vs 21%; OR 3.44), HAQ, and PASI outcomes with concurrent tirzepatide and biologic initiation, alongside markedly lower CRP (4.2 vs 7.7 mg/L; p<0.001) despite similar DAPSA LDA rates.

Synthesis

Weight loss clearly matters; DIPSA proves that. But the week-4 ACR50 divergence in TOGETHER-PsA, the BMI-adjusted disease activity signal in the Toronto cohort, the CRP reduction in Venerito’s series, and the DMARD persistence advantage in TriNetX all point toward effects that weight loss alone cannot fully explain. The RISE registry, meanwhile, confirms that PsA patients are already the most frequent GLP-1RA users in rheumatology, making the mechanistic question not merely academic but clinically urgent. Whether the observed benefits reflect direct GLP-1 receptor signalling in immune cells remains to be established. For now, rheumatologists should view GLP-1RAs as powerful allies in managing the obesity-PsA comorbidity burden, with growing evidence that their benefits extend well beyond the scale.

Sources

Coates et al., OP069 (TOGETHER-PsA); Eder et al., OP070 (DIPSA); Mehta et al., OP074; McCormick et al., OP0112 (RISE); Venerito et al., POS0050; Almodóvar et al., POS0194.